Navigation Links
PAREXEL International to Present at Morningstar Conference
Date:11/1/2012

BOSTON, Nov. 1, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Morningstar Conference in Chicago.  James Winschel, Sr. Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 9:30 a.m. CT on Wednesday, November 7, 2012.

A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at www.parexel.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until February 7, 2013.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 13,330 employees. For more information about PAREXEL International visit www.parexel.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contact:
Jill Baker, Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118
Email: Jill.Baker@PAREXEL.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. UV Flu Technologies Expands Its International Footprint
9. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
10. International Attendance for Networking and Education at Informex Beyond Manufacturing
11. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):